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Abstract
This article emphasises the role of domestic knowledge capabilities and networks in 
shaping an incentive structure for innovation and research. I combine an analysis of 
in-house research activities by ayurvedic firms in South India with their inter-firm and 
inter-institutional relations in the establishment of a new innovation regime aiming to 
promote growth in the ayurvedic sector. The tensions typical of this competitive envi-
ronment are discussed by paying attention to the absence of contingent regulatory 
practices and the recent efforts in this direction as illustrated by the use of the ‘Magical 
Remedies Act’ to curtail the claims of many firms in the market. The ayurvedic pharma-
ceutical company Oushadhi owned by the Government of Kerala as well as the private 
firms SNA Oushadhasala Pvt. Ltd. and Vaidyaratnam Oushadhasala Pvt. Ltd. (all from 
Thrissur district of Kerala) are analysed to delineate their research priorities and bottle-
necks for innovations. The data of this ayurvedic sector is contrasted with the case of 
the Kani tribe and the ways in which their traditional knowledge has been reformulated 
into an industrial ayurvedic product. Through this exploration, the paper attempts to 
offer an economic explanation for increasing reformulation practices in Ayurveda.
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 Introduction
Research and innovation in ayurvedic pharmaceuticals can be analysed in the 
context of an increasing competition with the biomedical pharmaceutical 
sector in India, the potential for market success and the challenges posed by 
the ethos and dominant parameters of science and modern medicine. In this 
context, the ayurvedic sector necessarily confronts two challenges: firstly, to 
carve out a recognisable economic space in the market and advance without 
challenging the dominance of science and biopharmaceuticals; secondly, to 
pursue ways for complying with internationally acceptable standards of trade 
practices, which are basically designed for biopharmaceuticals.1 The inter-
dependence of various stakeholders from within and outside the ayurvedic 
pharmaceutical sector and the geo-political context in which they operate, 
shape the kind of innovations that are feasible for growth and can be adapted 
to Ayurveda. This paper explores the innovative behaviour among ayurvedic 
firms in the context of recent policy developments. This, in turn, reveals the 
nature of reformulation practices that offers an economic explanation for the 
increase in the number of proprietary products on the market. Such an analy-
sis allows to explore incentives and constraints for innovations—both endog-
enous and exogenous to firms—and details the relevant policy steps required 
in terms of the institutional linkages necessary for the sector.
Bioprospectors and herbal pharmaceutical companies are interested in 
traditional plant-based medical knowledge, usually referred to as ‘traditional 
knowledge’—TK, mainly due to two developments: a) the increasing accep-
tance of traditional knowledge as a lead in the search for active ingredients 
and multi-ingredient compounds that can considerably reduce search costs 
1    India has a growing pharmaceutical sector, which accounts to about six to seven billion 
US $ in 2008, representing two per cent of India’s global market, and ranking fourth in terms 
of volume and thirteenth in value (Greene 2007). Ayurvedic pharmaceuticals form a very 
meagre share of the same and represent only two per cent of the global herbal market in 
terms of value (Madhavan 2011). The ayurvedic manufacturing industry is different from 
the general pharmaceutical industry, viz. source of knowledge, nature and process of drug 
discovery, scientific applications, fragmentation of markets, targeted consumer categories 
etc. It also has some similarities in terms of marketing strategies, institutional development, 
networking etc. The structure of the industry is analysed elsewhere (Madhavan 2009; Bode 
2008). Parallel to these well-developed codified systems of Ayurevda, Unani, Homeopathy 
and Siddha, India’s folk medicines also thrive. They have found a niche mostly in rural areas. 
In the context of the Kerala state, many folk and tribal healers continue to practise what 
their teachers had taught them, and what could be called a pre-codified indigenous system 
of healing that already existed in the past.
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and can occasionally indicate valuable leads for developing entirely new 
plant-based pharmaceutical drugs; and b) from a private industry perspec-
tive, the high cost of drug discovery2 and the impending patent expiration of 
many blockbuster drugs represent significant hurdles for future commercial 
viability.3 Also, the trade-related Intellectual Property requirements like prod-
uct patenting have been extended to many countries that, until now, have been 
dominated by generics. In this context, most of the ayurvedic products have 
to compete, not only with other products within the herbal category, but also 
with these newly emerging patented biopharmaceuticals.
In the last decade, a large number of biopharmaceutical giants have begun 
to take an interest in herbal divisions in their drug research4 (for example, 
Ozone Pharmaceuticals, Sami Labs, Hindustan Lever Ltd. etc.), whereas many 
small and medium-sized ayurvedic companies lack the personnel and the 
means to innovate patented or new molecule developing research. It is also 
true that many have preferred to stay away from the production of molecu-
lar research as they stick to the traditional trajectory, brand loyalty, and spe-
cific customer base. It makes the ayurvedic industry quite different from other 
industries in terms of taxation, access to resources, and even in market struc-
ture. The ayurvedic companies predominantly concentrate on the production 
of classical ayurvedic products (based on ayurvedic textual formulations) and 
a new category of proprietary products, which ensure them exclusive market-
ing rights in a monopolistic competitive environment and at times, they even 
hold a product monopoly.
I discuss the incentives and disincentives for ayurvedic firms to explore the 
determinants of the current innovative practices in the sector. This analysis 
is extended to understand the regulative structures in place in order to mini-
mise the malpractices inherent in the drug production scenario. To focus the 
analysis, I will discuss the Local Innovation and Production System (LIPS), 
which determines the nature of the innovations and the dimensions of inno-
vativeness in the sector. I argue here that the economic incentives for radical 
innovations in the strict sense of molecular innovations are largely crowded 
out by the structure and function of LIPS within Ayurveda, hence innovations 
2    It takes about 10 to 15 years to develop a new medicine from the time it is discovered to when 
it is available as a treatment. The average cost of researching and developing each successful 
drug is estimated to be 800 million US $ to one billion US $. This includes the cost of the thou-
sands of failures: for every 5,000–10,000 compounds that enter the research and development 
(R&D) pipeline, ultimately only one receives approval (CBO 2006).
3    Gehl Sampath 2005.
4    Arora 2005.
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mostly take place in the form of reformulation practices in drug production. 
Yet, reformulations per se could be considered as a major form of alternative 
innovation practices within the sector. The paper will also show that systemic 
incentives can introduce nuances in reformulation practices as in the case of 
the commercialisation of the traditional medical plant knowledge of the Kani.
 Three Postulations: Property Rights, the Innovation System and 
Trade Practices
To understand the innovation system5 in the ayurvedic sector, I consider three 
important and interrelated postulations. The first is to ascertain that there is a 
cost involved in the commercialisation of community knowledge. Many eco-
nomic models perceive knowledge as an exogenous public good. It is assumed 
to be available in every economy, as in Solow’s neo-classical formulation,6 and 
thus knowledge is not understood as a process or a practice. However, later 
theories, including the thinking of evolutionary economists, do not consider 
technological knowledge to be something that just happened to societies 
or economies,7 but as a process that every society needs to consciously and 
actively promote and nurture, for which certain socio-economic precondi-
tions must be met. The question is whether traditional knowledge also has the 
same features as a determinant of growth. We can assume that there are two 
possible types of growth involving traditional medical knowledge as a major 
source of input that differ only in the presence or absence of property rights. 
The first type is one in which the adequate protection of patents,8 ownership 
rights, and other incentive mechanisms are available to the actual knowledge 
holders, whereas in the second type, no incentive mechanisms are effectively 
5    The concept of ‘innovation system’ emerged as an alternative way to explain the innovation 
process, improving on an earlier view of simple linear progression of scientific research. The 
concept considers innovation as an outcome of interactions among firms, organisations, and 
institutions, in the context of historical, cultural, and socio-economic framework conditions. 
The innovation systems framework is useful in capturing knowledge flow in order to elabo-
rate policy.
6    Solow 1957.
7    Nelson and Winter 1982; Romer 1986; Lucas 1988.
8    Patents in ayurvedic research are given only in very exceptional cases, if the novelty and 
new avenues for the uses can be proven. So far, around 34 patents have been granted mainly 
under the research of the Central Council for Research in Ayurveda and Siddha (CCRAS) and 
another 13 patents have been filed within India. In addition, many technology transfers have 
also been encouraged (available at http://www.ccras.nic.in).
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established. When innovators fail to internalise (either through property rights 
or through other exclusive rights) the cost of (sharing) innovations, they will 
choose to keep their inventions secret, and hence the available knowledge and 
innovations will remain static. This means they will not be available for further 
innovations.9 Obviously there are other socio-economic reasons for keeping 
the knowledge secret in this case, such as the belief that efficacy would be low-
ered once it is shared, mishandling of the knowledge by others, etc.
In folk medicines,10 innovations tend to remain with the innovator due to 
the absence of efficient protective mechanisms and threat of mass exploita-
tion. Consequently, current innovations do not relate to previous ones because 
the innovator/physician chooses to keep them secret or might possibly be 
indifferent to the idea of putting them into the public domain.11 Therefore, 
innovations are continuous but non-additive or non-cumulative, production 
remains at the same level, the sector is static, and the production frontier does 
not expand. The costs of sharing knowledge include the risk associated with 
the loss of that knowledge, loss of livelihood, and an undermining of cultural 
belief. These losses need to be translated into financial costs/remuneration 
through contractual benefit-sharing if knowledge is to be accessed from the 
community. That means community-related knowledge can only be developed 
when there is adequate compensation for the community, which in turn, also 
involves administrative and procedural costs. So for a firm, it is always safer 
to work with knowledge from the public domain when lacking the support 
of a strong innovation system, where property rights are not defined. Ethnic 
groups protect their traditional knowledge through various mechanisms such 
as ‘term locking’—the use of an indigenous or colloquial term for the known 
medicinal plants in a herbal healing system. Various examples of this can 
be found in ethnic groups such as the Mudugar tribe of Attappady, Kerala.12 
Hence, much of the folk medical knowledge possessed by indigenous people 
does not reach professionally trained ayurvedic physicians or firms involved 
in the clinical development of ayurvedic drugs. This also holds true for the 
9     Nwokeabia 2002.
10    Unlike folk medicines, intellectual property of medical inventions is clearly defined in 
the bio-pharmaceutical sector, and one invention can prove to be the basis of a ‘ladder’ 
further spurring inventions and hence form a chain of added value through research. In 
the case of folk medicines (this includes all the practices which are not codified but orally 
transmitted through generations, mainly the tribal medical knowledge and knowledge of 
indigenous communities), a legally binding property right system is yet to be initiated, 
but also many cultural/therapeutic beliefs stop them from sharing the knowledge.
11    Madhavan 2011.
12    Unnikrishnan 2009.
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codification of knowledge, since many indigenous texts that carry the bulk 
of the knowledge have traditionally developed and improved formulas. For 
example, Sahasrayogam, Yogamrutham (Kerala origin) have never figured in 
any of the institutional syllabi. The 1992 Malleswara Project mentions that in 
the Bommiyampathy region of Attapady in Kerala alone, tribal populations 
make use of around 500 medications and plant knowledge that were com-
pletely unknown to the institutionalised system of Ayurveda. This also shows 
that considering folk medicine as a systematised knowledge has a character 
resembling eco-systems and customary follow-ups. Following on from my first 
postulation, any kind of knowledge inherent to a community or individual 
cannot be shared without an understanding of values attached to it and, more 
importantly, without a cost.
In the mainstream ayurvedic sector as well, research and bioprospection 
is developed into further cumulative innovations when adequate incentive 
mechanisms are established. At the macro level, defining knowledge rights 
remains a major hurdle in the development of the pharmaceutical sector. 
When working with public knowledge, i.e. in the case of classical formula-
tions, ‘creative reformulation’ for incremental innovations can be a feasible 
option for the firms; and this has radically redefined the sector over the past 
few decades. Here, property rights are ensured by branding the product with 
the firm’s name. These reformulations via incremental innovations may lead to 
a new product or process or a completely new form of the old product, which 
may at times qualify as a substitute to the former. It is worth mentioning that 
these ‘below the radar’13 innovations are relatively effective substitutes for 
many high-end drugs in developing countries.14
A contractual agreement with symmetrical information and a more partici-
patory approach to define the individual and community property may provide 
incentives for the community to preserve its knowledge and disclose it for fur-
ther commercial validation. Therefore, it is important to establish an incentive 
system, which takes the communities’ incentives for sharing knowledge into 
consideration, and encourages firms to practise effective bioprospection while 
using the resources sustainably. Many authors have highlighted the need for an 
efficient institutional (innovation) system, but scholars have generally ignored 
the social and normative institutions, which mainly represent the interper-
sonal relations and horizontal learning avenues that may strengthen values 
and support cumulative innovations.15 Furthermore, simply enforcing legal 
13    Clark et al. 2009.
14    Kaplinsky 2011.
15    Murray and Stern 2007; Murray 2005.
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rights may be a relatively blunt and costly instrument in shaping the socially 
complex processes of innovation since they ignore the substantive organisa-
tional and institutional context in which these interests are embedded.16
My second postulation is that the ayurvedic firm can be re-conceptualised 
as an organisation embedded within a broader set of formal and informal rules 
and a socio-economic–political environment reflecting historical and cultural 
trajectories. This understanding helps to avoid overemphasising research and 
development (R&D) in the innovation process, and encourages policy makers 
to take a broader perspective on the opportunities for learning and innovation 
in small and medium sized enterprises.17 Here, innovation is understood as a 
localised, context specific and socially determined process which implies, for 
instance, that the acquisition of technology abroad is not a substitute for local 
efforts. LIPS offer a distinctive framework to analyse these complex interac-
tions within the sector. Within this framework, the processes of generation, 
dissemination, and use of knowledge, as well as the productive and innovative 
dynamics, are understood. It encompasses a wide range of economic, political, 
and social actors and their interactions, including manufacturers, suppliers of 
raw materials, equipment and other inputs, distributors and marketers, work-
ers and consumers, organisations focused on education and training of human 
resources, information, research, development and engineering, support, regu-
lation and financing, civil society, cooperatives, associations, unions and other 
representative bodies.18 This technique brings the innovation systems into the 
foreground. The innovation system emphasises innovation as an outcome of 
interactions among firms, organisations, and institutions, in the context of his-
torical, cultural, and socio-economic conditions and localised learning inter-
actions that are necessary for the build-up of critical capabilities throughout 
the innovation system.19 It is a holistic approach to policy in order to influence 
and change innovation behaviour for improving productive performance.20 In 
innovation systems, the firm is placed at the centre and considered as the driv-
ing force.21 This is due to the fact that innovation is defined as ‘the implemen-
tation of a new or significantly improved product (good or service) or process, 
16    Scotchmer 1991, 1996.
17    Mytelka and Farinelli 2003.
18    Lundvall 1992.
19    Lundvall 1992; Bell and Albu 1999; Metcalfe and Ramlogan 2008; Kraemer-Mbula and 
Wamae 2010.
20    Freeman 1987; Nelson 1988; Lundvall 1992.
21    Izuka 2013.
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a new marketing method, or a new organisation method in business practices, 
workplace organisations or external relations’.22
Economists and policy analysts have ignored the role of previous innova-
tions or existing knowledge, and their exclusive focus on the ‘public good’ 
aspect of information deterred them from delving deeper into the distinctive 
properties of information, and particularly from the challenge of contracting 
for technological information.23 In this case, the cost of using tacit informa-
tion such as traditional knowledge reduces the public good argument since it 
is unlike other public information which can be transferred at negligible costs. 
So in a system in which these issues are not clarified or defined, stakeholders 
are unable to take the risk of venturing into an action to maximise their objec-
tive. Here, firms may not be able to invest in drugs because of the high cost 
involved in any drug enquiry. This lack of transparency probably results in less 
bioprospection activities and more proprietary and reformulated drug devel-
opment in Ayurveda.
A major ayurvedic manufacturer in Kerala noted:
If we go for bioprospection, it involves not only time and money but 
long periods of waiting to pass through various drug developing pro-
cesses, including clinical trials. There are many types of cost involved, 
such as the costs of finding the knowledge, ensuring the stakeholders’ 
benefit, difficulties regarding patenting and even more ensuring continu-
ous availability of raw materials and strong competition from many bio-
medical drugs. Even after we have passed through all these difficulties, if 
the invented drug enters the category of essential drugs, then it would be 
priced low. So we prefer to produce proprietary ayurvedic medicines to 
avoid all these headaches.24
My third postulation is that, given the relevance of the other two postula-
tions, a sector that depends on a complex innovation system and aims for a 
larger market presence can maximise its profits by taking the dominant trade 
practices into account and following them. The peripheral trade practices 
such as the sanitary and phytosanitary (SPS) measures25 and the policies and 
22    OECD and Eurostat 2005.
23    Gehl Sampath 2003.
24    Interview by the author with Managing Director, PKHL, Thiruvananthapuram, July 2008.
25    The WTO recognises internationally harmonised standards and encourages member 
countries to use them as a basis for their SPS measures in order to reduce distortions in 
market access. The SPS Agreement is consistent with the standards and guidelines of the 
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legislation in place, such as the Dietary Supplements and Health Education 
Act (US, 1994) in major markets of the US and EU, are relevant barriers of entry 
for ayurvedic firms, not to mention the fact that many firms have issues with 
good manufacturing practices, agricultural practices, and accepted preserva-
tives etc.
Through these three important postulations we may infer that, firstly, a 
well-defined property right system is important in incentivising the knowledge 
sharing process and by and large, the firms look for alternatives and cost effec-
tiveness that may keep them away from the complications of property and 
patenting issues. Secondly, differences in innovation structures may determine 
the probability of a break-through innovation or a social innovation being suc-
cessful and thirdly, given that Ayurveda is competing with the biomedical 
sector, its standardisation and manufacturing procedures may have to be mod-
elled on the dominant standardisation framework and that of the agreement 
on Trade Related Aspects of Intellectual Property Rights (TRIPS), if the inten-
tion is to produce for the international market. The current global health chal-
lenges require a careful bridging of innovations and intellectual property with 
public health goals. Incremental innovations and reformulation of ayurvedic 
knowledge in the public domain could be a means of renegotiating a place for 
Ayurveda in the contemporary competitive regime, if it is adequately backed 
by social innovations that find solutions for many social and medical issues 
(for example, the Ayurvedic Kit26 for nutritional programmes, products like 
Kamilari and Liv-52 for liver care, etc.). These new forms of innovations can be 
thought of as having the potential to improve the economic situation of the 
poor27 and may address an aspect of medical innovative development that has 
been overlooked in the past.
FAO and WHO with respect to food additives, pesticide residues, contaminants, hygienic 
practices, and methods of analysis and sampling for harmonising international rules in 
this field of trade.
26    In reaction to the spread of epidemics during the monsoon, Oushadhi, in association 
with the Indian System of Medicine (ISM) department, plans to distribute ayurvedic 
Epidemic Prevention Kits (EPK). Each kit would contain the classical ayurvedic prod-
ucts like Shadangam Kashaya Choornam, Guluchi Choornam, Avipathi Choornam, 
Thaleesapathradi Choornam, Viluadi and Sudarshanam tablets.
27    See Kaplinsky 2011 on innovations leading to national policies to stimulate economic 
growth for the benefit of poor people (primarily in the economic sense of poverty) and 
inclusive development.
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 Innovations and Reformulations in Ayurvedic Pharmaceuticals
Drugs and products developed from textual formulations cannot be patented 
but can obtain proprietary rights, since most of the products are simply an 
extension, addition, or deletion of one or more herbal ingredients in a given 
formula. In the case of proprietary drugs, the formulations can be ‘optimised’ 
to make them different and special. However, a specific licence has to be 
obtained in order to deviate from the classical text while ensuring nevertheless 
that the ingredients are the same as those listed there and that the processing 
methods are similar to those described in these authentic texts, while combi-
nations make them different.28 Thereby, alterations promoted by private sector 
manufacturers can also receive legal recognition. In addition, the products do 
not qualify for patent protection since the properties of novelty and inventive 
steps—the clauses necessary for product patents under the TRIPS regime—
do not hold. Hence, successful exploitation of knowledge in this sector largely 
focuses on innovations in the control and management of ‘complementary 
assets’ or supporting systems, in particular, the process of gaining regulatory 
approval, specialisation in incremental research in some known products, 
marketing and advertisements etc. Many of these factors act as powerful barri-
ers to entry for other firms. The market for such products are characterised by 
strong information asymmetries and consumers are typically unable to evalu-
ate drug quality. Many scholars have addressed the issues of multiple prod-
uct branding and the nebulous differences between varied product categories 
and different norms of product classification followed by different corporate 
companies.29 I do not intend to discuss these here in detail. Even in the classi-
cal formulations, the cost can differ as quality can be largely compromised by 
the use of second-best plants for the extension of the market through low cost.
As the head of R&D at Oushadhi points out:
We are not able to compete with many northern firms in the case of 
Haridra, because the cost of Haridra produced by Oushadhi is relatively 
high due to the quality control. Haridra has antiallergic, anti-inflammatory 
and antimicrobial properties. We sell at a high price because we use the 
quantity of milk along with ghee and manjal (turmeric, Curcuma longa) 
prescribed by the traditional texts, but this is not the same in the case of 
many branded companies and they do not add enough milk to the prepa-
ration. Also, they sell it in granule form, which saves a minimum of five 
28    See D&C Act 1940.
29    Bode 2008; Banerjee 2009.
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main days in production, hence the cost will be reduced and the output 
will go up. But Haridra should be produced in the most absorptive form 
(powder) for allergy and should be easily meltable.30
Traditional practices are often ignored in order to minimise the production 
costs. In the case of ayurvedic pharmaceuticals, standardisation essentially 
means ensuring the basic minimum quality, while allowing firms to innovate 
high quality products and position them differently in the market. The absence 
of radical innovations in Ayurveda render the new forms of reformulations 
in the industry no less important; on the contrary, they are imperative for 
the growth of the market. Pordié and Gaudillière describe reformulation in 
Ayurveda as the redefinition of knowledge and preparation practices focusing 
on the properties of complex medicinal materials to feed the emergence of 
autonomous pharmacy, but carried out mostly by experts who can manipulate 
medicinal combinations. They also underline the fact that at times, this may 
overlook humoral variabilities and depersonalise the act of healing.31
Evidence from a number of firms in Thrissur, Kerala is analysed in this sec-
tion, where enquiries were made concerning their R&D, reformulation, and 
innovation practices. Thrissur district has the largest growing number of 
ayurvedic medicine manufacturing companies in the state of Kerala, well-
established medicinal plant market and delivery system and effective inter-
linkages between the communities, state, firms, and other stakeholders of 
the sector. This data may help us to delineate the type of innovation under-
way in Kerala State, which is traditionally considered the home of authentic 
Ayurveda. The firms’ reformulation practices are evident from this analysis.
Generally, the R&D activities in Ayurveda can be broadly classified into three 
different types. The first is product research, development, and delivery of new 
drugs with enhanced performance in terms of cost, safety, and efficacy. The 
second type is standardisation and research that produces quality enhance-
ments. The third is medicinal plant research. The demarcation between plant 
research and product research is ambiguous since any product research neces-
sarily begins with botanical research. Research investment is skewed towards 
the second type, i.e. mostly standardisation techniques (see table 1).
30    Interview by author with Oushadhi R&D chief, May 2013.
31    Pordié and Gaudillière 2014.
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TABLE 1  Fragmentation of research expenditure (%) in different categories (info from 27 
firms)32
Number of firms in 
sample according to 
size
Product research Standardisation and 
quality check
Plant research
large firms 43 50 7
medium firms 31 63 6
small firms 19 75 6
Various national institutions such as the Indian Council of Medical Research 
(ICMR), the Council of Scientific and Industrial Research (CSIR), the 
Department of Biotechnology (DBT), the Department of Science & Technology 
(DST), the Central Council for Research in Ayurveda and Siddha (CCRAS), and 
the Central Council for Research in Unani Medicine (CCRUM) are involved in 
research into AYUSH (Ayurveda, Yoga, and Naturopathy, Unani, Siddha, Sowa 
Rigpa, and Homoeopathy). The ICMR has carried out research in traditional 
medicine on the validation of traditional knowledge in the areas of diabetes, 
filariasis (philariasis), benign hypertrophy of the prostate, coronary artery dis-
ease, cancer, HIV/AIDS, and so on, and the fingerprinting of selected herbal 
preparations, agrotechnology of selected plants for various clinical trials (e.g., 
Picrorhiza kurroa and Pterocarpus marsupium), and the development of new 
molecules from plant sources.33 There are a number of collaborative projects 
on a national level, but the New Millennium Indian Technology Leadership 
Initiative (NMITLI) and the Golden Triangle Initiative (GTI)34 projects require 
specific mention in the context of product research in association with the 
industrial field.
32    Primary survey by author, November 2012. I divide the firms into three categories: large 
firms are those which have a sales turnover of more than Rs. 100 million and medium 
firms are between Rs. 50 and 100 million and small firms are those below Rs. 50 million 
per year.
33    Banerjee 2008.
34    The Golden Triangle Partnership (GTP) 2005 is an innovative scheme with the Department 
of AYUSH, ICMR and CSIR as equal partners to study ayurvedic formulations using mod-
ern tools and technologies in order to (1) validate them as safe and efficacious therapies 
for Indian and global use, (2) identify a few formulations as complementary agents to 
modern drugs, (3) help the Indian traditional drug industry to scientifically standardise 
the raw materials and finished products for global acceptability of these drugs.
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NMITLI is the largest R&D scheme to boost public-private-partnership 
efforts in the country. It looks beyond today’s technology and thus seeks to 
build, capture, and retain a leadership position by synergising the best com-
petencies of publicly funded R&D institutions, academia, and private industry. 
The Government of India’s GTI project integrating biomedicine, modern sci-
ences, and traditional medicine is indicative of a trend in which traditional 
sciences such as Ayurveda are increasingly embracing a scientific evidence 
base and the spirit of robust research.35 R&D investment and collaborations 
are relatively higher among large firms such as Oushadhi, Vaidyaratnam, and 
SNA Oushadhasala.
In most of the firms, research funding constitutes less than two per cent of 
sales turnover (table 2). The survey showed that most of the quality control 
labs for raw materials are considered to be research labs. And the lion’s share of 
research money is actually spent on standardisation processes, not on product 
35    The Osteoarthritis project under NMITLI scheme involved a network of 16 national 
research institutions, modern medicine hospitals, and pharmaceutical industries from 
India (Patwardhan and Mashelkar 2009).
36    Author’s primary survey 2012. We have not received information about one major firm in 
Thrissur. SNA is incorporated in the major analysis as it seems to be one of the leading 
innovative firms.
37    Fixed capital is that portion of the total capital outlay that is invested in fixed assets 
(such as land, buildings, vehicles, plant and equipment), that stay in the business almost 
permanently—or at the very least, for more than one accounting period.
TABLE 2  General economic indicators of three leading firms in Thrissur district36
2010–11 2011–12
Oushadhi VRO SNA Oushadhi VRO SNA
Sales (Rs. Million) 379.3 475.3 61.1 453.1 535.1 73.1
Export % of sales Nil 73 25 Nil 67 38
Proprietary medicines (%) NA 19 72 NA 20 76
Fixed Capital37 
(Rs. Million)
124.5 17.0 1.0 138.8 17.0 1.0
R&D expenditure %  
of sales
0.34 1.1 1.4 0.66 2.0 1.6
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or process innovations or research leads. The most vibrant firm in research 
collaboration is the public firm, Oushadhi, though research spending within 
Oushadhi is lower than that of other firms. In terms of their innovative activi-
ties and irrespective of their size, most of them have innovative activities and 
produce more proprietary products than classical categories. VRO has substan-
tially increased the research account, especially for new product research. But 
new or improved process innovations are not very frequent in these small firms 
(table 3). However, many claimed to have made changes in product appear-
ance to suit the market demand and to make their products user-friendly. The 
expenditures on advertisements of two major firms comes around 5–8% of 
their sales turn over.
The innovations within Oushadhi are commendable. The firm has intro-
duced around 90 drugs to the market through various forms of innovations. 
The best example of process innovation is Pramehoushadhi, introduced by 
Oushadhi for diabetic patients in 1998, which has a turnover of Rs. 30 million per 
year as of 2014. It is the most demanded product by diabetic patients. Initially 
it was in granule form and later the market feedback led to its transforma-
tion into tablets, which was a success. Preclinical and long-term toxicity stud-
ies are conducted on Prameshoushadhi for this purpose. The challenge was to 
 
 
38    Joseph et al. 2013, p. 14. New products are defined as any products, including classical, 
which are new to the market. New process is an entire change in the combination or other 
process through which the drug is produced.
TABLE 3  Number of firms reporting varied innovative activities38
New 
Product/
Improved 
products
New/
Improved 
process
Quality 
change 
through 
technology
New raw-
material
Appearance 
changes
New 
organisation
Total
Oushadhi 32 14 30 5 4 4 90
VRO 27 16 5 2 4 5 59
SNA 42 13 1 0 09 0 65
other 
firms (50)
29 26 2 0 23 7
Madhavan250
asian medicine 9 (2014) 236–271
sustain the proportionate phytoclinical profiles of 500 grams in a 2.5 gram tab-
let. Challenges in monitoring changes through scientific parameters were also 
evident in the case of a burn cream when it was repositioned as a spray.
The case of Oushadhi demonstrates an effective industry-academia 
research link. Oushadhi has created various networks such as: a) a programme 
for producing bio-manure from bio-waste with Kerala Agricultural University; 
b) development of a medicinal plant nursery with state medicinal plant 
boards; c) collaborative research with central government institutions such as 
the Central Food Technologies Research Institute (CFTRI); d) collaboration in 
preclinical and clinical research and prototype development with Jawaharlal 
Nehru Tropical Botanical Garden and Research Institute ( JNTBGRI) (on a hep-
atoprotective drug) and Amala Cancer research centre; e) a national medici-
nal plant project related to linkages with various biotechnology departments 
of many colleges; f) various analytical research with the biosciences depart-
ment of Kannur University and Institute of Applied Dermatology, Kasaragod 
(learning disability products and for carpal tunnel syndrome); g) production 
and research collaboration with Central Council for Research in Ayurveda and 
Siddha (CCRAS); h) network with CARe Keralam (the innovation cluster in 
Ayurveda) to ensure the best quality of raw materials; and also i) interdisciplin-
ary projects and the validation of pharmaceutical products with many ayurvedic 
firms. The government department AYUSH has recently provided funding for 
Oushadhi as a Centre of Excellence for Ayurvedic pharmaceuticals (Rs. 50 mil-
lion). State government grants in aid and share capital have helped Oushadhi 
to step into many research collaborations. The share capital of the state gov-
ernment increased from Rs. 2.5 million in 2007–08 to Rs. 40 million in 2011–12.
Oushadhi have exclusive proprietary rights to market 32 reformulated 
drugs. Shelf-life and palatability were the elementary innovations in the case 
of the basic ayurvedic formulations. The most innovative companies are able 
to come up with a large number of new products and new processes. Oushadhi 
is even able to bring about innovations by creating new markets (for example, 
ayurvedic health drinks developed with the technical support of the Central 
Food Technological Institute, Mysore, and Ayurvedic Kit for nutritional devel-
opment). Oushadhi and Vaidyaratnam have links with many research labs, 
both governmental and private (for example, VR have links with NABL Mumbai 
for HPTLC and HPLC testing, with Mannuthi veterinary college for toxicology 
studies, and with Kottakkal Arya Vaidya Sala for pharmacology studies). Post-
graduate student projects in microbiology, biotechnology, and chemistry are 
another important source of innovations (some of the projects later funded 
by Oushadhi). An antifungal cream, research on methods of fermentations 
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especially in Chyawanpash and also understanding the new controlled fer-
mentation process of Asavarishtam (a form of fermented decoctions) and pro-
filing of various salts used in Ayurveda with the help of modern chemistry, 
are some of the new possibilities Oushadhi is exploring with these projects. 
Student research results were used in the preparation, storage, and fermenta-
tion of this product in its commercial application. Oushadhi is emerging as 
one of the major institutions for clinical trials in Kerala.
My research results show that the major incentives for engaging in R&D and 
innovation are technology change and self-motivation of firms for creating a 
better market. One of the innovations of Everest Pharmaceuticals of Thrissur is 
a discovery of the means to increase shelf-life without preservatives. Kashaya 
has been converted into choornams (micro-granules) to reduce raw-material 
wastage and enhance palatability. The cost of these micro-fine powders proved 
to be lower, and multi-layered sealed packing with metallised polyester with 
low-density plastic is used to ensure longer shelf-life. The marketing method 
for this product is ethical promotion and no advertisements.
Other instances of reformulations are those emerging from industry- 
academia contact, in the case of Oushadhi this was via the TBGRI eth-
nographic expedition. A new product—a hepatoprotective and psoriasis 
drug—developed from community knowledge is soon to be introduced to the 
market. TBGRI has also entered into an agreement for a three-phase clinical 
trial with Oushadhi on a new liver tonic. The product is in granule form and 
is obtained from three plants. Two of the plants are from the Acanthaceae and 
Cannabaceae families; the third is a bioenhancer like the popular Thippali. 
Once the clinical trials are completed, Oushadhi will apply for a joint pat-
ent. Oushadhi also plans to conduct year-long clinical trials of the product on 
patients with liver disorders before launching it commercially. The results of 
trials on animals clearly show that the tonic can be administered as a medicine 
for patients with history of jaundice, hepatitis, and in early stages of liver cir-
rhosis. It can also be used as an antidote to alcohol-related blackouts. Since the 
late 1990s, Oushadhi developed into a profit-making enterprise. At the same 
time, Oushadhi had almost entered into the reformulated drugs based on clas-
sical categories and also started flourishing setting-up outlets all over the state 
and also outside of Kerala. Now Oushadhi supplies medicines to many state 
governments even in North India. These innovative attempts and research 
collaborations helped Oushadhi to recover from its financial loss from 1995 
onwards.
The research capabilities of traditionally experienced physicians are used 
by many firms as one of the important solutions for dealing with quality 
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standards and treatment; as many as 19 firms have adopted this strategy.39 This 
could even contribute to the growth of the overall system as many of the ear-
lier innovations were informal and confined to isolated physicians. Many small 
firms have fewer interactions in the field. This limits their ability to learn in 
terms of technology transfer and adoption. Traditional physicians do help 
these firms to cross-check the impact of new technology. Safe, hygienic, and 
quality-tested reformulation of existing drugs rather than entirely new prod-
ucts seems to be the most pertinent strategy.
The responses from the firms showed that the most important sources of 
innovations are interaction with the R&D enterprises and government labs, 
competitive initiatives, and in-house research (table 4). Many classical ayurvedic 
medicines have been given a new appearance as pills and choornams (powders). 
Translating the subjective parameters (like traditional cross-checking of 
quality manually) into objective criterions is a cumbersome process. The 
important issue is the pertinence of traditional standards in the mechanisa-
tion process. Further research is needed on issues of scale to understand 
 
 
39    Conversation with the main physician at KMA Oushadhasala, Guruvayoor.
40    Based on author’s primary survey, conducted during November 2012.
TABLE 4  Sources of innovations40
Firms High Medium Low
Oushadhi nil R&D enterprises, govt. 
research organisations, 
universities, customers, 
competitors, within  
enterprise experiences
consultants
VR commercial labs and 
R&D enterprises
competitors within enterprises
SNA within enterprises competitions, consultants 
and research labs and  
R&D enterprises
Govt. research 
organisations and 
clusters
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modern technologies in manufacturing. The use of stainless steel instead of 
mud vessels and measuring the putative influence on medicinal properties 
was a major challenge in manufacturing. Rather than promoting an increase 
in product varieties, the firms need to concentrate on technology transfer to 
obtain better standardisation. The firms hold the opinion that most of the 
over-the-counter (OTC) products in Ayurveda make huge profits for a maxi-
mum of 5–7 years and then disappear from the market altogether, some due 
to increasing competition, others due to unethical practices in production 
and lack of efficacy studies on new combinations. The two recent examples 
from Kerala are Lavana Thailam (an anti-obesity medicine) from Ayurcare and 
Musli Power Extra (an aphrodisiac) from Kunnath Pharmaceuticals. Very few 
products are able to sustain their success over a long period.
My survey reveals that the impact of regulation and standards, cost of inno-
vations, and weak financial incentives are the major reasons for lack of viable 
and radical innovations in the sector. The financial incentives and perks for the 
researchers in ayurvedic companies seem to be much lower than that of bio-
pharmaceutical firms. It has shown that a post-graduate ayurvedic physician is 
paid on average Rs. 15000–20000 monthly in the research labs, which is quite a 
disincentive for the young personnel in the sector. This is quite similar in both 
private and public sector and this actually attracts the young ayurvedic doctors 
to find their earnings in the newly emerging ayurvedic tourism industry, where 
they are paid much better. An interesting fact is that many ayurvedic post-
graduates have taken management degrees to actually serve the tourism indus-
try as marketing managers and medical tourism promoters with a therapeutic 
background. And most of the researchers within the firms have not received 
any career promotions and individual incentives, and support in terms of pub-
lications in their own name or other financial benefits are largely lacking.
In terms of interactive learning, apart from Oushadhi, the firms do not par-
ticipate in many interactive innovations or knowledge transfers (Table 4). But 
the recent development of Confederation of Ayurvedic Renaissance—Keralam 
Limited (CARe Keralam), an innovation cluster in Kerala, R&D and other 
necessary pharmaceutical developments now work as a catalyst for increas-
ing inter-firm relations and innovative incentives among smaller firms.41 At 
present, the innovation system, determined by inter-firm relations and mutual 
learning, seems to be under-developed in the mainstream ayurvedic market 
and most of the product-process innovation decisions are made in accordance 
with external factors such as political economy of global market, regulatory 
frameworks, and financial availability.42
41    For details, see Madhavan 2013.
42    Banerjee 2009; Madhavan 2011.
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Formerly, India practised a dual tariff structure in which a higher rate of taxa-
tion was paid for proprietary medicines while ayurvedic medicines were sub-
ject to a lower rate. When ‘ingredients tests’ became the touchstone, the courts 
held that if the predominant ingredients in the drug are mentioned in authen-
tic ayurvedic texts, then they should be treated as ayurvedic, irrespective of 
whether they were used in an allopathic or an ayurvedic system. The net result 
was that a uniform rate of taxation for all medicines came to be adopted.44 
Section 10 (contents of specification) of the Patents (Amendment) Act, 2002,45 
provides that the applicant must disclose the source and geographical origin 
of any biological material deposited in lieu of a description. Also Section 25(1) 
(j) relating to any opposition to granting a patent, as amended, allows for an 
opposition to be filed on the grounds that the complete specification does not 
disclose, or wrongly mentions, the source of geographical material used for the 
invention. This synchronised approach adopted by India, whereby the patent 
law and central excise tariff work in tandem, will encourage patent holders to 
disclose whether they have derived any benefit from traditional knowledge; 
they may then be required to make a contribution to the holder of the tradi-
tional knowledge pool but will benefit from lower central excise tariffs. This 
encourages firms to continue producing ayurvedic reformulated drugs. India’s 
argument in WTO is on the same lines regarding the derivative drugs from tra-
ditional knowledge.
One of the suggestions that the firms reiterated is the need for an inclu-
sive innovation system based on the size of the firm.46 The government has a 
‘one size fits all’ policy, which hinders their ability to compete with the bigger 
firms. Intervention of the excise department in the quality assessment and the 
forest department in raw material collection was cited as the reason for the 
abstinence of small operators in the field. Other suggestions included a single 
window for information regarding quality criteria and patenting queries and 
a rigorous shift in policy environment for enabling the exports of small firms. 
They also demanded a better laboratory support, subsidised electricity, pro-
tection from wildlife laws, and stringent forest rules. It is imperative that the 
ayurvedic community is familiar with the differences between quality stan-
dards, regulatory affairs, R&D, and clinical standards. Many firms said that the 
Minor Forest Product Laws, procurement regulations and even advertisement 
44    Arora 2013.
45    The Patents (Amendment) Act, 2002 is the second of three amendments to the Patents Act 
of 1970 to bring India’s patent regime into compliance with the WTO TRIPs Agreement. 
This Act was introduced with the new Patent Rules, 2003, which replaced the earlier 
Patents Rules, 1972.
46    Mahaoushadhi Herbal Remedies, Avanoor and Kodakkatil Ayur Links, Kandanissery.
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rules all present hurdles to an innovative environment within the industry. 
They also suggested that the regulation systems should not be based on the 
Ayurvedic Pharmacopeia of India (API) since it covers only a few of the formu-
lations in the diverse canonical texts. From the interactions it was clear that a 
transparent institutional arrangement is pertinent in communicating and fol-
lowing up the regulatory regimes of various departments in this sector, which 
may enhance and foster innovative practices in small firms.
 Local Innovations and Production Systems in Reformulation:  
The Kani Case
In the case of traditional industries like Ayurveda, bottlenecks such as high 
transaction costs and risks, weak information flows, weak institutional envi-
ronments, and a number of other constraints often inhibit successful innova-
tion systems. Using the Triple Helix model of university-industry-government 
relations, Leydesdorff 47 proposed configurational information to provide an 
indicator of synergy in Triple-Helix relations. This model enables us to distin-
guish knowledge functions in innovation systems. Agents are geographically 
positioned and endowed, but are able to exchange irrespective of these bound-
aries in economic relations.
FIGURE 1  Network of knowledge and innovation systems.48
47    Leyesdorff 2006.
48    Ibid.
Knowledge
exploration
Knowledge
exploitation
Scientific/technological
knowledge creation
Economic
exchange
relations
Geographical
location
Organizational
control
Innovation
system
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The institutional and organisational elements of innovation systems can be 
called as the ‘organisational control function’. ‘Exploitation’ is associated with 
the reuse of existing competences and ‘exploration’ with the creation of new 
alternatives. At the systems level, mechanisms of knowledge exploitation rep-
resent the interface between economic welfare and technological knowledge 
creation. This interface does not necessarily depend on geographical locations 
because economic welfare is created at the level of global markets, even if cer-
tain technologies originate in single regions. A more nuanced analytical under-
standing of institutions and markets should both demand and promote greater 
understanding of (a) the processes and types of institutional change needed 
for local systems and communities to escape from ‘low level equilibrium traps’, 
and (b) the need for pragmatic, path-dependent, and location-specific mixes 
of investment, in non-standard institutional arrangements as well as in the 
institutional environment. The case of the Kani indigenous polyherbal medi-
cine Jeevani is an excellent example of an efficient self-motivated partnership 
that avoided many of these low-level equilibrium traps. A synergised institu-
tional model could be an imperative strategy to sustain these successful part-
nerships, which was lacking in the case of Kani knowledge sharing.
The deal was brokered between JNTBGRI, a research institute in Kerala, 
India, and the Kani tribe who live in the Agastya forests of Kerala state, whose 
traditional knowledge of the invigorating properties of the arogyapacha plant 
(Trichopus zeylanicus) was used to create the energy boosting drug Jeevani. 
This case depicts the way in which various bottlenecks of bioprospection 
were overcome with an effective industry-academia-community network. 
It is clear that the issues such as search costs, incentives for revelation of 
knowledge, defining property rights, efficient technology transfer, and benefit 
sharing—the major bottlenecks of bio-prospection—were avoided through 
the institutional networks. The lessons from the Jeevani case open up the pos-
sibility for marginalised communities to benefit from bioprospecting deals 
and underlines the efficiency of an institutional approach to conservation 
and development problems. Although various aspects of this model have been 
questioned,49 the success of drug discovery from the indigenous knowledge, 
the community-academia-market interaction, and the initiative for a pre-CBD 
(Convention on Biological Diversity, 1992) benefit sharing process constitutes 
to a large extent the dynamics of the innovation system. The knowledge com-
munity here interacted with outsiders, the state, and authorities on a daily 
basis and close commercial, personal, and social links were frequently devel-
oped between the ethnic group and outsiders. The knowledge was divulged 
 
49    Anuradha 1998; Bijoy 2007.
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after a tacit agreement with the community that the benefits would be shared, 
if it was commercialised. Hence, the issues of transaction cost and information 
access were, to a certain extent, avoided with this tacit contract.
JNTBGRI is an autonomous research organisation that was established by 
the Kerala state government in 1979 to conserve biodiversity. A detailed scien-
tific investigation of arogyapacha was conducted, including chemical screen-
ing to isolate the active principles, and pharmacological screening. They 
realised that the classical pharmacological approach to the study of herbal 
drugs of isolating active principles in the form of single compounds is far from 
satisfactory for the understanding of traditional practices. Hence an ethno-
pharmacological approach was adopted to evaluate the plant from the point 
of view of the theoretical foundation of a well-organised system of medicine, 
i.e. Ayurveda. The plant was identified as Trichopus zeylanicus travancoricus, 
which had been documented before, but its traditional use and special proper-
ties were not known. A study of the leaves revealed the presence of certain gly-
colipids and non-steroidal compounds that had anti-stress, anti-hepatotoxic, 
and immunomodulatory/immunorestorative properties. The last phase of 
the research was conducted at JNTBGRI, where the drug Jeevani was for-
mulated with Trichopus zeylanicus and three other medicinal plants as 
ingredients.50 Withania somnifera or ashwagandha was used in the formula-
tion of the drug; the application mentions that ashwagandha is an important 
drug in ancient ayurvedic literature. Toxicity, shelf-life, and clinical studies 
were carried out by the institute. This was a unique reformulation experience 
in the ayurvedic sector, different from the numerous proprietary combinations 
on the market. In short, this method has not used any existing combinations in 
the authentic texts of Ayurveda, but taken the cue from traditional knowledge 
and then it did seek an explanation from ayurvedic texts, i.e. it could be vārāhi 
in Ayurveda. Subsequently researching on various properties of the plants they 
have disseminated relevant therapeutic contact of the drug through reputed 
papers in journals. Later a formulation was identified through combinations of 
other medicinal plants, as we mentioned earlier. The research and standardi-
sation procedure was mostly co-ordinated by government research labs with 
contributions from JNTBGRI, hence a synergetic innovation system emerged. 
This reformulation was part of an effort to obtain the marketing rights and 
ayurvedic principles, nomenclature, and the regulatory structures were used 
to obtain proprietary approval for the product.
This model is also an excellent example of a public-private partnership. 
The technology has been transferred to Arya Vaidya Pharmacy for which an 
agreement was signed between JNTBGRI and Arya Vaidya Pharmacy in 1995. 
50    Anuradha 1998.
 259Innovation System and Increasing Reformulation Practices
asian medicine 9 (2014) 236–271
The duration of the licence was seven years. JNTBGRI received a 2 per cent 
royalty on the drug sales. An effective drug discovery was possible in the case 
of Jeevani, due to an effective interaction between various institutions—
JNTBGRI, the Kani trust, and Arya Vaidya Pharmacy, Coimbatore. This is an 
example of community-academia-market interaction for effective ayurvedic 
drug formulation and marketing, stemming from community-based knowl-
edge. The ethnic groups have benefited in different ways, notably in medicinal 
plant production (USD 1,500 in a year).
Defining property rights is often a concern in the case of benefit-sharing 
models. Here, this problem was surmounted with the formation of Kerala Kani 
Samudaya Kshema Trust (KKSKS) and on September 1997, the due amount of 
USD 13,000 was transferred to the account of the Trust, of which USD 12,500 
was 50 % of the licence fee and the rest was the first instalment of the royalties. 
The KKSKS is left to decide whether to utilise only the interest ensued over the 
licence fee and royalty. Up to 2003, a sum of USD 2,500 was obtained in royal-
ties from the sale of the drug. This was passed on to the trust, in addition to 
many other benefits in kind.
The raw material department was probably the only area where this model 
ran into trouble. It failed to incorporate the forest department in sustainable 
cultivation, which later impacted upon the larger sustainability of the model 
itself. Even though it has been argued that the benefit-sharing mechanisms 
in the case of the Kani were not prolonged—possibly due to the raw material 
planning, information asymmetry of the market, political interference etc.—
Jeevani’s reformulation method has now led to a number of pipeline products, 
notably for diabetics and asthma. Now Jeevani will be marketed by Oushadhi 
for the next seven years, but with another innovation in appearance, i.e. a 
change to powder form. This procedure is yet to start its function. A new con-
tract is also ready to be signed with the forest department for the cultivation in 
its own micro forest habitat.
 Recent Policy Initiatives in Regulatory Practice
 Initiatives Concerning Standards
A recent WHO survey showed that around 90 countries, less than half of WHO’s 
Member States, currently regulate herbal medicines. Moreover, there are 
disparities in regulation between countries, which has serious implications 
for international access to and distribution of such products.51 This makes 
 
51    WHO 2004.
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production norms difficult for the industry. In the last decade, the central gov-
ernment and AYUSH initiated a number of policy regulations to ensure the 
safety and efficacy of ayurvedic drugs and to reduce non-scientific practices 
in ayurvedic proprietary products. There is a constant demand for scientific 
validation of the principles on which the Ayurveda, Siddha, and Unani (ASU) 
systems are founded, particularly of the efficacy and safety of the therapeu-
tics. Such a demand has motivated a large number of investigations in clini-
cal research and drug standardisation studies. Although such projects have 
been pursued over decades, the outcomes have been limited.52 Chapter IV A 
(regulation of ASU drugs) of the Drugs and Cosmetics Act 1940 (D&C Act 1940) 
suggests that drug licences are a state matter and that firms can obtain them 
from any responsible state institution. Proprietary drugs need special licences 
as they differ from classical drugs in terms of their combinations, even though 
the processing methods and the ingredients are the same. But for many rea-
sons most of these policies are not seriously implemented. The absence of 
required drug officials is one of the major problems. For example, in Kerala, 
there are only three AYUSH drug inspectors in the entire state to deal with qual-
ity control of thousands of new ayurvedic drugs. Lack of quality enforcement 
of ingredients and gaps in the fulfilment of procedures prescribed in classical 
drugs leave enough room for the manufacturers to tweak the formulations and 
make incorrect shelf-life claims. Chandra shows that through interactions with 
licensing authorities from states with a large number of manufacturing units 
and very few officials, it was apparent that the approval is granted on the basis 
of the manufacturer’s claims.53 A large number of licences were issued even 
before batch assessments or label checks were carried out.
Some recent policy changes have been introduced: batch-wise testing for 
heavy metal content, labelling leniency (the label can be presented accord-
ing to the exporting country’s rules) to improve the export market (2000), a 
strengthening of state pharmacies and drug testing authorities, ‘essential drug 
lists’ in Ayurveda for a standardised supply of medicines to government dis-
pensaries and hospitals etc. Kerala is the only state which has an ayurvedic 
drug controller. But efforts in this direction, with more monitoring officers 
and transparency in regulation procedures, is warranted. The raw-drug trade 
is currently completely handled by private players, while the avenues of co-
operative models need to be explored.
The 2008 amendment to the D&C rules stipulates that firms keep raw mate-
rial records for the previous year to show their actual consumption of raw drugs. 
52    Chandra 2011.
53    Ibid.
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Very importantly, administrative orders have been issued to ban misleading 
prefixes and suffixes in classical and proprietary ASU medicines. In effect, this 
particular order prevents the branding of classical medicine. The manufactur-
ing companies were given a one-year transition period to sell the products they 
had already manufactured, starting from October 2013. By attaching a prefix or 
suffix, the companies are branding the classical ayurvedic products for their 
economic benefits (e.g. Dabur Chyawanprash, Himalaya Chyawanprash etc.). 
Many companies sell Chyawanprash Sugar Free, Chyawanprash Ginger, and 
other such products, which are not mentioned in classical ayurvedic texts. 
Another two important enforcements are: firstly, shelf-life/date of expiry—
the D&C rule (161B) in 2010 ensures that the medicine is within the limit of 
longevity, and secondly, the introduction of a new category called ‘ayurvedic 
cosmetics and supplements’ to support exports in 2010. The second enforce-
ment requires all clinical trials to be registered and botanical names to be 
mentioned on the product labels. The table below explains the recent policy 
changes that the industry and the State of India are currently debating. Various 
sub-committees with different terms of reference have been formed to deal 
with the manufacture, clinical trials, and safety of the pharmaceuticals. The 
initiatives are evidence of an increasing regulatory control over malpractice in 
the name of Ayurveda.
TABLE 6  The sub-committees with different terms of reference on regulation54
Sub-committees under Ayurveda Siddha 
Unani Drugs Technical Advisory Board 
(ASUDTAB)
Terms of references
1. Subcommittee to examine Schedule 
 ‘Z’ and other relevant notification
Introduction of Schedule ‘Z’ in Drugs & 
Cosmetics Rules 1945—related to 
requirement & guidelines for permission 
to manufacture ASU drugs for sale or to 
undertake clinical trials
2. Subcommittee to evaluate the 
 proposed Retail Sale Licence for 
 ASU drugs
Introduction of Retail sale licence for ASU 
medicines containing Schedule E (I) drugs 
(poisonous substance) of the Drugs & 
Cosmetics Rules 1945
54    Ibid.
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Sub-committees under Ayurveda Siddha 
Unani Drugs Technical Advisory Board 
(ASUDTAB)
Terms of references
3. Subcommittee to review the Model 
 Laboratory Practices for testing of 
 ASU drugs
Amendments in Drugs & Cosmetics Rules, 
1945, for introduction of Schedule-T-1 
related with ‘Good Laboratory Practices & 
Requirements of premises & equipment 
for testing of ASU Drugs’
4. Subcommittee to amend First 
 Schedule of Drugs & Cosmetics Act, 
 1940, for the list of Authoritative 
 ASU books
Frame the Amendment of the list of 
authoritative books in the First Schedule 
of Drugs & Cosmetic Act, 1940, with 
details of writer, publisher, year of 
publication etc.
5. Subcommittee to examine shelf-life 
 of ASU Medicines
Review of shelf-life of Siddha and 
Ayurvedic drugs mentioned in respective 
formularies and under Rule 161-B, 2 (ii) of 
the Drugs & Cosmetics Rules to harmonise 
the shelf-life of drugs to rectify ambigui-
ties between Formularies and legal 
provisions
One of the affirmative actions that the state authorities have taken recently is 
to use the existing Act to regulate the sector. For example, in Kerala the gov-
ernment clamped down on the dubious claims of three companies promis-
ing magical remedies. In 2011, under the Drugs and Magic Remedies Act 1955 
concerning ‘objectionable advertisements’ the Kerala Drugs Control authori-
ties initiated legal action against the distributors of five ayurvedic compa-
nies including Dabur India Ltd. for their sale of products using misleading 
advertisements.55 This could be the first case of its kind where the rules were 
effectively used against ayurvedic giants. In 2012, the Kerala Drugs Controller 
took action against the ayurvedic giants for violating provisions of the Drugs 
and Cosmetics Act & Magic Remedies Act and almost Rs. 20 million worth 
of products were seized. The manufacturing companies found to be violat-
ing the provisions concerned Dhathri Ayurveda Pvt. Ltd., Cochin Ayurvedic 
Centre (Indulekha hair oil), and Sreedhareeyam Ayurvedic Medicines Pvt. 
55    Kunnathoor 2011.
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Ltd. The advertisements for Indulekha Bringha Complete Hair Oil, Dhathri 
Fair Skin Cream, and Sreedhareeyam Smartlean were found to be misleading. 
It was also claimed that these products were being sold at exorbitant prices. 
Warnings were issued under section 33 E of the DCA for false or misleading 
claims and section 4 of the Drugs and Magic Remedies Act 195456 for objec-
tionable advertisements.
In order to ensure standards for traditional medicines, the Department of 
AYUSH with support from the Quality Council of India (QCI), has introduced 
two brands: Premium mark and AYUSH mark. This is part of the voluntary 
product certification scheme that the Department of AYUSH has been explor-
ing for selected AYUSH products to enhance consumer confidence. The scheme 
is based on a criteria for certification. It has two levels: a) AYUSH Standard 
Mark which is based on compliance to the domestic regulatory requirements; 
b) AYUSH Premium Mark which is based on GMP requirements according to 
56    Subject to the provisions of this Act, no person shall take any part in the publication of 
any advertisement relating to a drug if the advertisement contains any matter which (a) 
directly or indirectly gives a false impression regarding the true character of the drug or 
(b) makes a false claim for the drug or (c) is otherwise false or misleading in any material 
particular.
57    Kunnathoor 2011.
TABLE 7  Violations of DMRA captured by Kerala drug controller department 57
Product Marketing company/Outlet Producer Company
Dabur Sree Gopal Thailam Tali enterprises in 
Kozhikode
Dabur India
Primafit capsules Fortune Herbals Sulthan 
Batheri
Fort Herbals, Palakkadu
Kamagold capsules Ultra Marketing Kannur 
district
Laborate Pharmaceuticals, 
Panipat
Balovita Massage Oil Anu Pharma Kasaragod Balona Herbals, 
Moovattupuzha
Herbuosutra capsules Distributor of Vedic  
Pharma Kozhikodu
Vedic Pharma, Kochi
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WHO Guidelines and product requirements with flexibility to certify against 
any overseas regulation provided, these are stricter than the former criteria. 
Under this scheme, each manufacturing unit would obtain a certification 
from an approved certification body (CB) which is accredited to appropriate 
international standards by the National Accreditation Board for Certification 
Bodies (NABCB) and will be under regular surveillance of the certification 
body. However, there are very few takers for these products. The Ayurvedic 
Pharmacopeia Committee has produced voluminous literature on standards, 
but there is no reference material available in the market, which actually 
reduces the relevance of the whole exercise.58
Even now, what is left to discuss in the manufacturing of ayurvedic med-
icine is an effective price control of drugs. Even though tax exemptions are 
given, it is not reflected in the prices of classical drugs and hence medicines 
are not cheaply available as before. This may be for various reasons, like the use 
of more and more technology, increasing depletion and import of medicinal 
plants, increasing labour costs, impact of the wellness element, and a steep 
increase in domestic demand etc. The lack of an effective pricing strategy per 
se is a reason for the increase in drugs. In Kerala, the earlier pricing strategy 
was path dependency, following the major firm, i.e. Kottakkal Arya Vaidya Sala. 
Now the method has been moved into cost plus pricing strategy, in which the 
margin is solely determined by the firm. An effective price control of various 
categories would have, no doubt, a greater public health impact.
 Initiatives Concerning IPR
In another significant move, the government of Kerala released an Intellectual 
Property Rights (IPR) policy document in 2008. Since the constitutional pow-
ers of the Indian state government in the matter are limited, the document 
reveals the state government’s approach to certain selected issues of practical 
importance for Kerala in the context of the new IPR regime, while eschew-
ing general obiter dicta on that regime.59 The document argues that traditional 
medical knowledge obviously cannot be transformed into private property 
and nor can it be put in the public domain. However, putting it in the public 
domain, while preventing direct private patenting of existing knowledge, can-
not prevent their indirect private appropriation through any kind of claimed 
‘improvements’.
58    Chaturvedi 2013.
59    Patnaik 2008.
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The basic elements of the legal arrangement suggested in the documents for 
the protection of traditional knowledge are the following:60 a) all traditional 
knowledge, including traditional medicine, the practice of which sustains live-
lihoods, must belong to the domain of ‘knowledge commons’ (common people 
who hold the knowledge, not any enterprises or larger entities), and not to 
the ‘public domain’; b) in the case of community knowledge, this custodian 
will be deemed to have rights over the knowledge, while in the case of knowl-
edge that is spread out, the Kerala state will be deemed to have rights over 
the knowledge; c) no entity that is registered as a medium or large enterprise 
may be deemed to have any rights over traditional knowledge; d) the right-
holders will have two kinds of rights: firstly, the right, where applicable, to a 
‘brand name’ or a name associated with the unique practice of an institution 
or community or family, such as ‘Kottakal massage’61 and secondly, the right to 
the use of the knowledge; e) everybody else, other than the right-holder to the 
knowledge, who wishes to use it, will have to do so under a ‘commons licence’; 
f) any use of traditional knowledge or practice in violation of the ‘commons 
licence’ within or outside the state of Kerala will be considered a violation of 
the rights of the right-holders and will invite prosecution.62 All rights hold-
ers of traditional knowledge will be deemed to be holding their rights under a 
‘commons licence’. Under this licence, the right holder permits others the use 
of the knowledge for non-commercial purposes. If any development is made 
using that knowledge, it will have to be put back into the ‘knowledge com-
mons’ and cannot be patented anywhere. For commercial use by others, an 
agreement would have to be reached with the rights holders. To operate this 
legal arrangement, a body named the Kerala Traditional Knowledge Authority 
(KTKA) is proposed, with which all practitioners of traditional knowledge of 
the first category will have to be registered.
This document, not yet officially implemented in Kerala, raises important 
policy debates in the context of our discussion. For example, a) given that 
some of this knowledge, such as Ayurveda, is not just confined to Kerala, how 
can the State arrogate all rights over it? Consider the case of the Kanis and aro-
gyapacha; this tribal group is not confined to the state of Kerala, but extends 
over to the state of Tamil Nadu. Would the Kanis on the other side of the fence 
face prosecution, if they grow and use arogyapacha? b) Importantly, there is a 
60    Intellectual Property Rights Policy for Kerala (2008) URL: <http://www.wipo.int/edocs/
lexdocs/laws/en/in/in048en.pdf>, last accessed 4 November 2013.
61    Reference to Shamnad Basheer’s writing, URL: <http://www.Spicyip.com>, last accessed 
1 July 2008.
62    Patnaik 2008.
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complete bar against patenting any ‘improvement’ or other advancement of 
such knowledge by either the community or any of their licensees. In a scheme 
that resonates with the open source licensing movement, any improvements 
made using that knowledge have to be ploughed back to the ‘knowledge com-
mons’, the question here is, would families or communities that desire to work 
with industry to capitalise on their closely guarded knowledge subject them-
selves to such restrictions, knowing that an open source approach may make 
the deal a bitter one for the industry? c) In the case of community or family-
owned traditions, does this policy offer sufficient incentives for these families 
or communities to disclose their closely held (and in most cases, almost ‘trade 
secret’ like) knowledge?63 The incentive structure for reformulation as in the 
case of the Kani may be annulled in the context of implementation of this 
regime. We have seen that both economic incentives without an institutional 
structure and a full-fledged innovation system without symmetrical informa-
tion flow and incentives can harm the ‘below the radar’ reformulation struc-
ture of the sector. How far the clusters such as CARe Keralam can successfully 
circumvent or challenge these new issues and entice reformulations is a dif-
ficult question to answer.
In another important initiative, the Patent Cell (Traditional Knowledge—
Innovation Kerala Project) in Kerala was formed in 2003 under the Directorate 
of Ayurveda Medical Education with the objective of protecting the traditional 
knowledge in Ayurveda. The Patent Cell has published a book with the title 
Keraleeya Oushadha Vijnanam (Information on Kerala’s Drugs) by using the 
data obtained from ancient palm leaf manuscripts. It was proposed to estab-
lish a centre for traditional knowledge innovation in Kerala. An amount of 
Rs. 10 million is provided for the strengthening and continuance of the scheme 
during 2014–15.
 Conclusion
In a strict economic sense, the innovation system for drug discovery in 
Ayurveda is not yet well developed and is still battling with the issues of stan-
dardisation, inefficient regulatory structures, inadequate human resources etc. 
The non-additive64 character of innovations in Ayurveda is partly explained 
by the nature of its innovation system, especially the ill-defined property 
63    Basheer 2008.
64    Traditional medical knowledge innovations, especially the improvements in practice 
and new formulations respective to the individual and ecological differences, may not be 
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rights and lack of institutional co-ordination. Recently, most of the develop-
ments in the ayurvedic medicine sector, importantly, are mediated through 
drug reformulations. This is because the firms are less incentivised to invest in 
technological research due to the various costs involved in the complex pro-
cess of bioprospection and partly due to the difficulty of valuating biological 
resources and identifying the social costs.65 Evidently, many incremental inno-
vations in the form of reformulations work as forms of alternative pharmacy, 
which in turn address the ‘pro-poor’ health needs neglected by mainstream 
drug research. Research should be initiated in tropical drugs and regional epi-
demiology, where Ayurveda could play a crucial role. The universalisation of 
India’s health agenda envisions an effective inclusion of indigenous medicine, 
and reformulation practices if adequately regulated have a huge potential for 
an inclusive public health strategy through South-South cooperation and vari-
ous regional network models.
This paper reiterates that innovations with a social purpose can be gen-
erated through multiple local learning processes through mutual interac-
tions between various institutions and effective use of regulations within 
the system. The various socio-political and cultural contexts (which could be 
termed as Institutions A) and policy organisations, processes, and regulations 
(Institutions B) on the one side, along with science and technology initiatives 
in the manufacturing regime and market and demand on the other side decide 
the nature of interactive relations between firms among themselves and firms 
and the state. This ‘Local and Production Innovation System’ (LIPS) would 
form and mediate the firm’s behaviour in pricing strategy and also in forms of 
market creations. Hence I argue that, in the mentioned context of ayurvedic 
medicine, the ‘innovation system’ that has emerged is effective for a reformula-
tion regime as envisaged by various evidences.
Malpractices in the name of reformulation can be tackled using the 
Magical Remedies Act and subsequent new regulatory regimes as in the case 
of Kerala. Three important postulations explain the nature of innovations in 
the mainstream ayurvedic sector—the cost of knowledge transfer, firms, and 
pharmaceuticals as the leads for development and dominant trade practices 
as a determinant of firm behaviour. On the other side, we have examples 
like Oushadhi, whose efficiency is demonstrated by their research results 
in a number of reformulated medicines via interactive learning and inter-
firm knowledge transfers and the Kani people’s knowledge where multiple 
known to the other innovators as the property rights are not defined and confined to the 
informal settings.
65    Madhavan 2008.
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stake-holder interactions worked to form a new reformulation regime. These 
examples should contribute to the learning process of macro research pro-
grammes. The cluster approach in Ayurveda is an initiative for a mutual 
growth model. In recent decades, the Indian government has initiated various 
protection environments, such as the Traditional Knowledge Digital Library 
(TKDL), and the Ministry of Environment and Forests established a National 
Biodiversity Strategy and Action Plan (NBSAP) and National Biodiversity Act 
2002.66 However, growth of the sector may be hampered if incentives are 
not prioritised. Many developing countries with large traditional knowledge 
resources cannot capture or even enter the market, due to the absence of inno-
vations and lack of existing incentives. Research in the sector should also grow 
beyond new forms of marketing or modifying product appearance to work 
towards a growth-ladder model learning. Reformulations such as Jeevani could 
be genuinely enhanced with the co-ordination of an effective institutional sys-
tem in the way that I have proposed here.
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